The company restated 2024 results, cutting revenue by €45M and EBITDA by €31M, while forecasting 2026 revenue in the lower half of its range.
Gerresheimer completed its compliance and accounting review, receiving an unqualified audit opinion for 2025 but booking €258 million in impairments tied to development projects and its Chicago plant. The restatement reduced 2024 revenue by €45 million and EBITDA by €31 million, exceeding prior estimates.
2025 revenue rose to €2.3 billion due to the Bormioli Pharma acquisition, though organic growth remained nearly flat. The company forecast 2026 revenue in the lower half of its target range and negative free cash flow before M&A, citing weak primary packaging glass demand.
CEO Uwe Röhrhoff stated the company has completed forensic investigations into bill-and-hold accounting and other compliance issues, emphasizing a focus on governance and transformation.